Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | IDO1 | P14902 | 2/20 | 0.64 |
| ▸ | AGXT | P21549 | 2/20 | 0.64 |
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7040986 | 0.83 | CYP3A4 (0.64) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL28404628 | 0.82 | CYP3A4 (0.69) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL10866481 | 0.82 | CYP3A4 (0.69) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL1855225 | 0.80 | CYP3A4 (0.67) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL27543274 | 0.79 | CYP3A4 (0.60) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL423396 | 0.79 | CYP3A4 (0.60) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL13278842 | 0.78 | CYP3A4 (0.64) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL7958908 | 0.78 | CYP3A4 (0.64) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL4950985 | 0.78 | CYP3A4 (0.64) | CYP3A4IDO1AGXTPNMTMAOB | |
| SCHEMBL403680 | 0.78 | IDO1 (1.00) | CYP3A4IDO1AGXTPNMTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | claimed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | claimed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| EP-2617578-B1 | HEAT-SENSITIVE CHROMOGENIC COMPOSITION AND HEAT-SENSITIVE RECORDING MATERIAL FORMED USING SAID COMPOSITION | YAMAMOTO CHEMICALS INC (JP) | 2015-02-25 | — | — | EP | disclosed |
| US-8888906-B2 | Heat-sensitive color-developing composition and heat-sensitive recording material comprising the composition | YAMAMOTO CHEMICALS, INC. (JP) | 2014-11-18 | — | — | US | disclosed |
| EP-2617578-A1 | HEAT-SENSITIVE CHROMOGENIC COMPOSITION AND HEAT-SENSITIVE RECORDING MATERIAL FORMED USING SAID COMPOSITION | Yamamoto Chemicals, Inc. (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | XIN ZHILI (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1550661-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
| EP-1475374-A1 | THIADIAZOLE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | disclosed |
| EP-0961776-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CYP3A4 4653/4885IDO1 4109/4885AGXT 2996/4885 |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | CYP3A4 4493/4885IDO1 3192/4885AGXT 721/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | CYP3A4 3438/4885IDO1 4638/4885AGXT 3821/4885 |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | CYP3A4 4363/4885IDO1 2152/4885AGXT 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.